Alexion Pharma (ALXN) Tops Q4 EPS by 40c, Revenues Beat

Alexion Pharma (NASDAQ: ALXN) reported Q4 EPS of $2.96, $0.40 better than the analyst estimate of $2.56. Revenue for the quarter came in at $1.59 billion versus the consensus estimate of $1.52 billion.

• 4Q20 total revenues of $1,591.8 million, a 15% increase over 4Q19
• 4Q20 GAAP diluted EPS of $2.42; non-GAAP diluted EPS of $2.96
• Announced agreement to be acquired by AstraZeneca; transaction expected to close in Q3 2021
• Received EU approval for ULTOMIRIS® (ravulizumab) 100 mg/mL higher concentration formulation in paroxysmal nocturnal hemoglobinuria (PNH) & atypical hemolytic uremic syndrome (aHUS)
• Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020

"In 2020, we delivered on our LEAD-EXPAND-DIVERSIFY strategy - progressing our commercial portfolio with multiple global regulatory approvals, and further building our pipeline, which now spans more than 20 development programs. I am so proud of our team's remarkable execution and perseverance amidst the uncertainties of COVID-19," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. "We enter 2021 with significant momentum, a strong foundation and a promising future. I am confident we are well positioned to build on our success and further advance our mission of delivering life-changing medicines to people with rare diseases and devastating conditions in the coming months and once we become part of AstraZeneca."

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c